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Abstract
 
In addition to releasing preformed granular proteins, polymorphonuclear leukocytes (PMNs)
synthesize chemokines and other factors under transcriptional control. Here we demonstrate
that PMNs express an inducible transcriptional modulator by signal-dependent activation of
specialized mechanisms that regulate messenger RNA (mRNA) translation. HL-60 myelocytic
cells differentiated to surrogate PMNs respond to activation by platelet activating factor by ini-
tiating translation and with appearance of specific mRNA transcripts in polyribosomes. cDNA
array analysis of the polyribosome fraction demonstrated that retinoic acid receptor (RAR)-
 
 
 
,
a transcription factor that controls the expression of multiple genes, is one of the polyribosome-
associated transcripts. Quiescent surrogate HL60 PMNs and primary human PMNs contain
constitutive message for RAR-
 
 
 
 but little or no protein. RAR-
 
 
 
 protein is rapidly synthesized
in response to platelet activating factor under the control of a specialized translational regulator,
mammalian target of rapamycin, and is blocked by the therapeutic macrolide rapamycin, events
consistent with features of the 5
 
 
 
 untranslated region of the transcript. Newly synthesized
RAR-
 
 
 
 modulates production of interleukin-8. Rapid expression of a transcription factor under
translational control is a previously unrecognized mechanism in human PMNs that indicates
unexpected diversity in gene regulation in this critical innate immune effector cell.
Key words: inﬂammation • innate immunity • gene expression • translation • transcription
 
Introduction
 
The human polymorphonuclear leukocyte (PMN) is a crucial
effector cell in the innate immune system. PMNs are the first
myeloid leukocytes to respond to tissue damage or microbial
infection and initiate bacterial phagocytosis and killing. Acti-
vated PMNs use a repertoire of rapid response mechanisms
to accomplish wound surveillance and bacterial containment.
These include inside-out signaling of 
 
 
 
2
 
 integrins with con-
sequent increased cell adhesiveness and aggregation, polariza-
tion and directional migration, degranulation of preformed
proteins, and generation of oxygen radicals (1).
Besides acute responses, there is now evidence that
PMNs mediate inflammatory events over hours and can
express new proteins and polypeptides, including chemo-
kines (2). Soluble agonists, receptor-mediated phagocytosis,
and integrin engagement dramatically alter levels of messenger
RNA (mRNA) transcripts in human PMNs, and many of
these gene products are under transcriptional control (2–5).
New evidence also indicates that transcription is important
in the regulation of PMN apoptosis and, thus, the duration
and intensity of inflammation (1, 6). Although control of
this process in activated PMNs is incompletely understood,
key transcription factors are clearly central modulators. For
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example, constitutively expressed NF-
 
 
 
B translocates from
the cytoplasm to the nucleus in agoinist-stimulated PMNs
where it binds to promoter motifs and regulates transcrip-
tion of specific genes in regulated and dysregulated inflam-
mation (2, 7, 8).
Here, we report a previously unrecognized mechanism
of gene regulation in activated PMNs that involves unique
interplay at posttranscriptional and transcriptional check-
points. Critical posttranscriptional pathways are currently
recognized with increasing frequency as analysis of the hu-
man genome proceeds, and there is now clear evidence
that posttranscriptional dysregulation is a mechanism of
disease (9–11). Posttranscriptional control at translational
checkpoints may be particularly important in biologic sys-
tems in which factors with potent activities are precisely
synthesized with respect to timing and magnitude and in a
cell-specific fashion (9–11). These features characterize
synthesis of chemokines, cytokines, and other factors by ac-
tivated PMNs (1–8). In the studies reported here, we found
that, in response to cellular activation, PMNs rapidly trans-
late constitutive mRNA encoding the retinoic acid recep-
tor (RAR)-
 
 
 
, a nuclear hormone receptor and transcription
factor that regulates the expression of multiple downstream
genes in a variety of cells (12). In PMNs stimulated with
platelet activating factor (PAF), translation of RAR-
 
 
 
 mRNA
is controlled by the intracellular signaling kinase mamma-
lian target of rapamycin (mTOR), a specialized regulator of
translation that we have found recently to respond to out-
side-in signals in human PMNs (13). The newly synthe-
sized RAR-
 
 
 
 protein then modulates expression of the
chemokine IL-8. These observations identify a previously
unrecognized mechanism in the inflammatory portfolio
used by PMNs in which they modulate synthetic outcomes
by rapid, regulated translation of a critical transcription
factor.
 
Materials and Methods
 
Reagents.
 
PAF, AM-580 (an RAR-
 
 
 
–specific agonist), and
the anti–human RAR-
 
 
 
 monoclonal antibody were purchased
from BioMol. Puromycin, propidium iodide, heparin, and cyclo-
heximide were obtained from Sigma-Aldrich. Rapamycin was
purchased from Calbiochem. Trizol and Trizol LS total RNA iso-
lation reagents were purchased from Invitrogen. The 
 
32
 
P-labeled
dATP (PB10204, 250 
 
 
 
Ci/
 
 
 
L) was obtained from Amersham
Biosciences. The anti–human CD71 (transferrin receptor) mono-
clonal antibody and goat anti–mouse HRP-conjugated secondary
antibody were obtained from Biodesign. A second anti–human
CD71 (transferrin receptor) monoclonal antibody was purchased
from Immunotech. The anti–human 
 
 
 
-actin monoclonal antibody
was purchased from ICN Biomedicals, Inc. ProteaseArrest and
EDTA were purchased from Genotechnology Inc. Fura-2 was ob-
tained from Molecular Probes.
 
Polymorphonuclear Leukocyte Isolation.
 
PMNs were isolated from
healthy adult donor heparinized whole blood (75 U heparin/10
ml) using techniques described previously by our laboratory (14).
The procedures were approved by the University of Utah Insti-
tutional Review Board. Isolated PMNs were resuspended in
HBSS (BioWhittaker, Walkersville) with 0.5% human serum al-
bumin (Baxter Healthcare Inc.) to a concentration of 15–20 
 
 
 
10
 
6
 
 cells/ml. Purity of the human PMNs was 
 
 
 
95%.
 
HL-60 Cell Culture and Differentiation.
 
Cells of the human pro-
myelocytic leukemia HL-60 cell line were obtained from Ameri-
can Type Culture Collection and grown in Iscove’s Modified
Dulbecco’s Medium (BioWhittaker) supplemented with 20% FBS
(Hyclone), penicillin G, and Streptomycin (BioWhittaker). Am-
photericin B (Sigma-Aldrich) was added to the culture medium
(2.5 
 
 
 
g/ml). The cell cultures were passed biweekly to maintain
logarithmic growth. For these experiments, 2 
 
 
 
 10
 
6
 
 HL-60 cells
were resuspended in fresh media and were then differentiated
along the PMN (granulocytic) lineage with 1.3% DMSO (Ameri-
can Type Culture Collection) for 6 d (15) (also see Selection for
Differentiated HL-60 Cells and Assessment of HL-60 Differentia-
tion). Viability was assessed by exclusion of 0.2% Trypan blue
(Sigma-Aldrich) and was routinely 
 
 
 
80% after differentiation.
 
Selection for Differentiated HL-60 Cells.
 
The purity of differen-
tiated HL-60 surrogate PMNs was increased by negative selection
in which cells that expressed the transferrin receptor (CD71)
were removed (16). HL-60 cells treated with DMSO as above
were incubated with the mouse anti–human CD71 (transferrin
receptor) monoclonal antibody (1 
 
 
 
g/ml) for 30 min. The CD71-
positive cells were complexed to magnetic microbeads coated
with goat anti–mouse IgG (Miltenyi Biotec) and subsequently re-
moved by passage through a magnetized column.
 
Assessment of HL-60 Differentiation.
 
Differentiation of HL-60
cells to surrogate PMNs (HL-60 PMNs) (15) was assessed by sev-
eral criteria including nuclear segmentation, loss of transferrin re-
ceptor expression (16), and gain of responsivity to PAF (17). Im-
munocytochemical and flow cytometric analyses were used to
detect transferrin receptor expression. Immunocytochemical ex-
periments were done according to our previously published pro-
tocols (18), and the cells were examined with a Bio-Rad Lab-
oratories confocal microscope (Hercules). Flow cytometry was
performed on a Becton Dickinson FACScanner using minor
modifications of previously published protocols (16, 19). PAF-
induced cytosolic calcium influxes were assayed using a Shimadzu
spectrofluorophotometer after incubation with the calcium sensi-
tive fluorescent dye Fura-2 (Molecular Probes) (20).
 
Isolation of Polyribosomal RNA from Differentiated HL-60 Surro-
gate PMNs for mRNA Expression Array Analysis.
 
For polyriboso-
mal profiling experiments, we used differentiated HL-60 surro-
gate PMNs rather than primary PMNs to minimize difficulties in
maintaining integrity of leukocyte RNA during cell fractionation
and transcript analysis (21). Differentiated HL-60 PMNs (25 
 
 
 
10
 
6
 
 cells/sample) were left quiescent or stimulated with PAF
(10
 
 
 
8
 
 M) for 1 h at 37
 
 
 
C. The cells were lysed, and ribosomal
profiling was conducted using minor modifications of procedures
that we have described elsewhere (22). Total RNA was isolated
from the polyribosomal fractions from each sample and used to
generate 
 
32
 
P-dATP labeled cDNA, which was then employed as
a template in expression analysis (Atlas Human Cancer cDNA
Expression Array, 7742–1; CLONTECH Laboratories, Inc.).
 
RAR-
 
 
 
 Protein Expression.
 
Differentiated HL-60 PMNs or
freshly isolated primary human PMNs (2.5 
 
 
 
 10
 
6
 
) were resus-
pended in M-199 media (37
 
 
 
C) and left quiescent or activated
with PAF in indicated concentrations at 37
 
 
 
C in 5% CO
 
2
 
. In se-
lected experiments, the cells were pretreated (30 min) before ac-
tivation with specific translational inhibitors (puromycin, cyclo-
heximide, and rapamycin). At the indicated time points, the cells
were incubated with ProteaseArrest/EDTA (100
 
 
 
) for 5 min at
room temperature to prevent protein degradation. The cells were
pelleted and then lysed in 200 
 
 
 
l of 1
 
 
 
 Laemmli buffer (0.025 M 
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Tris, pH 6.8, 4% glycerol, 2% SDS, 1% 
 
 
 
-mercaptoethanol,
0.25% bromophenyl blue). Samples were stored frozen at 
 
 
 
20
 
 
 
C
until SDS-PAGE and Western analysis was conducted as de-
scribed previously (23).
 
RAR-
 
 
 
 and IL-8 mRNA Expression.
 
Quiescent or PAF-stim-
ulated human PMNs were lysed in Trizol reagent, and total
RNA was isolated via a modification of previously described
methods (24). SuperScript II or M-MLV reverse transcriptase
(Invitrogen) was then used to generate cDNA. The cDNA was
used for a PCR reaction designed to amplify a 233-bp product
generated using primers against the RAR-
 
 
 
 gene sequence (sense
5
 
 
 
-GGAGCTCATTGAGAAGGTGC-3
 
 
 
; antisense 5
 
 
 
-TTGA-
GGAGGGTGATCTGGTC-3
 
 
 
). Primers designed to amplify a
530-bp sequence of the GAPDH gene were used as an internal
control. In selected experiments, primers specifically constructed
based on the RAR-
 
 
 
1 (5
 
 
 
-CTGTCTGCCTCCCTTCTGA-3
 
 
 
)
and RAR-
 
 
 
2 (5
 
 
 
-CCACCCCTAATCCCTTCCT-3
 
 
 
) isoforms
(25) were used with a primer common to the coding region of
RAR-
 
 
 
1 and RAR-
 
 
 
2 (see Characterization of the 5
 
 
 
-Untrans-
lated Region of the RAR-
 
 
 
 mRNA Using Rapid Amplification
of cDNA Ends). For real time PCR measurements, we purchased
premixed PCR primers against RAR-
 
 
 
 (Hs00230907_m1) and
IL-8 (Hs00174103) and separate primers for GAPDH (GAPDH
Probe [designated “Joe”], GAPDH forward, GAPDH reverse).
The Bio-Rad Laboratories iCycler IQ (Hercules), the MJ
Research, Inc. Opticon 2, and Applied Biosystems 7900 HT
real-time PCR analysis systems were used to generate quantita-
tive measures of the expression of RAR-
 
 
 
, IL-8, and GAPDH
mRNAs.
 
Characterization of the 5
 
 
 
-Untranslated Region of the RAR-
 
 
 
mRNA Using Rapid Amplification of cDNA Ends.
 
Total RNA was
isolated from unstimulated human PMNs and used to generate
first-strand rapid amplification of cDNA ends (RACE)–ready
cDNA using reagents purchased from CLONTECH Laborato-
ries, Inc. with the Smart RACE cDNA Amplification kit. The
sequence for the 5
 
 
 
-untranslated region (UTR) of the RAR-
 
 
 
mRNA was amplified by PCR using the nested universal primer
supplied by CLONTECH Laboratories, Inc. and a specific
primer directed at the conserved regions of the RAR-
 
 
 
 gene
(5
 
 
 
-CCCCATAGTGGTAGCCTGAG-3
 
 
 
). The RAR-
 
 
 
 5
 
 
 
-UTR
fragments were ligated into a pCR 2.1 vector and cloned into
INF
 
 
 
 
 
Escherichia coli
 
 bacteria supplied with the TA Cloning kit
(pCR II, pCR 2.1) purchased from Invitrogen. Plasmid DNA
was extracted and prepared for sequencing using a QIAprep Spin
DNA Miniprep kit with supportive reagents purchased from
QIAGEN. An Applied Biosystems ABI 3700 96-capillary se-
quencer operated by the DNA Sequencing Core Facility at the
University of Utah was used to obtain sequences from the 5
 
 
 
-
UTR containing plasmid DNA. DNASis software (MiraiBio)
was used for analyzing the secondary structure of the 5
 
 
 
-UTR of
the RAR-
 
 
 
 mRNA.
 
Detection of IL-8 Protein.
 
Freshly isolated human PMNs were
incubated with PAF (10
 
 
 
8
 
 M), AM-580 (10
 
 
 
6
 
 M), or the com-
bination of both reagents at 37
 
 
 
C in 5% CO
 
2
 
 for various times.
For other experiments, we used the same conditions with and
without rapamycin pretreatment (10 nM) for 1 h. The superna-
tants were collected and frozen at 
 
 
 
20
 
 
 
C until analysis by
ELISA. IL-8 protein levels were quantitatively assessed using the
human IL-8 DuoSet ELISA system from R&D Systems accord-
ing to their protocols. Standard 96-well ELISA plates with sam-
ples were analyzed using SOFTmax for Macintosh Elisa software
(Molecular Devices) and a Molecular Devices THERMOmax
Microplate Reader.
 
Online Supplemental Material.
 
In Fig. S1, HL-60 cells were
cultured, differentiated, and characterized as described in preced-
ing sections. In Fig. S2, PMNs were isolated, stimulated with
PAF, and IL-8 mRNA and protein were analyzed as outlined
Figure 1. PAF regulates translational responses in differentiated HL-60
PMNs. (A) Ribosomal profile of HL-60 PMNs that were left quiescent
(red tracing) or activated with 10 nM PAF for 1 h (black tracing). These
profiles are representative of three independent experiments. Total RNA
was isolated from the polyribosome peaks and used to generate cDNA for
microarray analysis (as described in Materials and Methods and Table I).
(B) The top panel illustrates RAR-  and GAPDH mRNA expression in
PAF-stimulated HL-60 PMNs as measured by semiquantitative RT-
PCR. (Dividing lines indicate elimination of additional time points and
blank lanes between individual samples from the figure.) The middle
panel displays RAR-  mRNA levels as measured by real-time PCR.
The bars indicate the fold change in RAR-  mRNA copy numbers
compared with control (Co) cells at baseline, which was arbitrarily set at 1.
The tracings immediately above the bar graph indicate the amplification
curves for each time point. The bottom panel demonstrates Western blots
of RAR-  protein expression in differentiated HL-60 PMNs under control
conditions or when stimulated with PAF. The results in B are representa-
tive of three independent experiments. 
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Table I.
 
  mRNAs Expressed in Polysomes of Quiescent and PAF-stimulated HL-60 PMNs
 
Messages expressed in polysomes of quiescent HL-60 PMNs only
GRB10
BCL2-related protein A1 (BCL2A1)
Caspase 6
CD27BP (Siva)
RXR- 
Messages expressed in polysomes of quiescent and PAF-stimulated HL-60 PMNs
Cell division protein kinase 6 (CDK6)
Cyclin-dependent kinase inhibitor 1A (CDKN1A)
Peptidyl-prolyl cis-transisomerase nima-interacting 1 (PIN1)
Prefoldin 5 (PFDN5)
Vimentin (VIM)
LPS-induced TNF  factor (LITAF)
Ras homolog gene family member A (RHOA)
Erb-3 proto-oncogene
TNF receptor 2 (TNFR2)
Villin 2 (VIL2)
Ninjurin 1
Nucleoside diphosphate kinase   (NDK )
Rho-GAP hematopoietic protein C1 (RGC1)
Rho-GDP dissociation inhibitor 1 (RHO-GDI1)
Cadherin 5 (CDH5)
Early growth response protein 1 (EGR1)
Interferon   antagonist
Interleukin 1 receptor antagonist protein (IL1RA)
Interleukin 1 
Messages expressed in polysomes of PAF-stimulated HL-60 PMNs only
Cyclin-dependent kinase 4 inhibitor 2D (CDKN2D)
Wee1Hu CDK tyrosine 15 kinase
CDC10 protein homolog
Ubiquitin-conjugating enzyme E2
CDC37 homolog
Proliferating cyclic nuclear antigen (PCNA)
Growth factor receptor-bound protein 2 (GRB2)
B-raf proto-oncogene (RAFB1)
Myeloid cell leukemia protein 1 (MCL1)
Glutathione S-transferase–like protein
Chromatin assembly factor 1 p48 subunit
Growth arrest and DNA damage inducible protein 153
Ubiquitin-conjugating enzyme E2 17-kD
UV excision repair protein RAD 23 homolog A
RAR- 
Aggrecan 1 (AGC1)
CD 59 glycoprotein
Integrin  8
Malignant melanoma metastasis-suppressor gene
Interferon   receptor   subunit
mRNAs for key proteins are differentially associated with polysomes of quiescent and PAF-stimulated HL-60 PMNs. IL-8, which was examined
elsewhere in these studies, was not represented in the array used for these experiments.Yost et al. 675
above. Figs. S1 and S2 are available at http://www.jem.org/cgi/
content/full/jem.20040224/DC1.
Results
The mRNA for RAR-  Is Found in Polyribosomes of PAF-
stimulated Surrogate PMNs. PMNs release an array of ba-
sally stored granular proteins into the inflammatory milieu
(1). In addition, they expand their proteomic repertoire by
synthesizing new proteins, many of which are under tran-
scriptional control, in response to cellular activation (2, 13,
26, 27). To date, only a limited number of newly synthe-
sized proteins have been identified, and the molecular
pathways that regulate their production are largely un-
known (13, 27). To characterize additional genes under
signal-dependent control, we first profiled mRNAs associ-
ated with polyribosomes (polysomes), an index of active
translation (28), in resting and activated HL-60 surrogate
PMNs. Polysome analysis provides an approach that links
genomic and proteomic determinants of cellular phenotype
(28). Differentiation of HL-60 cells along the PMN lineage
was confirmed by segmented nuclear morphology, gain of
responsiveness to PAF, and loss of transferrin receptor ex-
pression (15–17) (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20040224/DC1).
Unstimulated HL-60 PMNs displayed typical ribosomal
profiles (22, 28) consisting of 40S and 60S ribosomal subunit
peaks and an intact 80S single ribosome peak, with smaller
polysome peaks in the gradient (Fig. 1 A). When we stimu-
lated these cells with PAF, a potent inflammatory phospho-
lipid that rapidly activates PMNs (13, 29, 30), the heights of
the 40S and 60S ribosomal subunit peaks decreased, and in
parallel the height of the 80S monosome peak increased
(Fig. 1 A) indicating translation initiation (10). We then ex-
amined patterns of mRNAs associated with polysomes in
resting and activated surrogate PMNs by cDNA microarray
analysis (22) to identify transcripts undergoing active transla-
tion (28). We found 28 mRNAs that were differentially as-
sociated with polysomes in PAF-stimulated cells compared
with unstimulated HL-60 PMNs (Table I). One transcript
of particular interest was RAR- , a nuclear hormone re-
ceptor that binds retinoic acid (12). The RAR-  gene is
best known as the target of chromosomal rearrangement in
acute promyelocytic leukemia (31). Although RAR-  has
not been identified in terminally differentiated mature PMNs,
it modulates the commitment of pluripotent hematopoietic
progenitors to the neutrophil lineage (32). Because the RARs
directly and indirectly regulate transcription of multiple gene
products (12), appearance of the mRNA encoding RAR- 
in polysomes in response to activation of HL-60 surrogate
PMNs suggested that it may represent a key checkpoint in
PMN synthetic pathways.
RAR-  Transcripts Are Constitutively Expressed in Resting
HL-60 PMNs and Are Translated into Protein in Response to
Cellular Activation. Translocation of RAR-  mRNA into
polysomes of HL-60 PMNs was rapid, occurring within 1 h
of activation with PAF. When we measured total RAR- 
mRNA in resting and PAF-stimulated cells by standard and
Figure 2. Cellular activation rapidly induces RAR-  protein expression
from constitutive mRNA in human PMNs. (A) The top panel illustrates
RAR-  and GAPDH mRNA expression in control (Co) PMNs or
PMNs activated with PAF as assayed by semiquantitative RT-PCR. The
middle panel illustrates RAR-  mRNA expression as measured by real-
time PCR. The bars represent the fold change in RAR-  mRNA copy
number compared with baseline (Co), which was arbitrarily set at 1. The
tracings immediately above the bar graph show the amplification curves
for each time point. The bottom panel illustrates RAR-  protein levels
in control PMNs or PMNs stimulated with PAF over a 4-h time period.
(B) A Western blot demonstrates RAR-  protein expression in PMNs
stimulated with PAF over the course of 1 h. (c) RAR-  protein expres-
sion in PMNs activated with PAF after preincubation with control buffer
or actinomycin D was examined by Western analysis. The same samples
were also probed for  -actin. Experiments in this figure are representative
of at least five independent studies.Translation of the Retinoic Acid Receptor-  by PMNs 676
quantitative PCR, we found that it is present in unstim-
ulated HL-60 PMNs and that its levels are only minimally
altered by activation (Fig. 1 B). We then examined cor-
relation of this constitutive RAR-  mRNA with the pro-
tein product in these cells. Only low levels of RAR-  pro-
tein were present in unstimulated HL-60 PMNs at baseline
(Fig. 1 B, bottom) even though the transcript was present
(Fig. 1 B, top). However, RAR-  protein dramatically ac-
cumulated within 60 min after cellular activation (Fig. 1 B,
bottom) consistent with the observation that RAR- 
mRNA associates with polysomes in PAF-activated HL-60
PMNs. These data indicate that constitutive RAR- 
mRNA is mobilized to polysomes in HL-60 PMNs stimu-
lated with PAF where it is then efficiently translated. This is
consistent with a mechanism in which expression of the
protein product is regulated at translational checkpoints (9,
10, 13, 28).
RAR-  mRNA Is Constitutively Expressed in Primary Human
PMNs and Is Translated into Protein in a Signal-dependent
Fashion. Although differentiated HL-60 PMNs exhibit
features of circulating human neutrophils (see The mRNA
for RAR-  Is Found in Polyribosomes of PAF-stimulated
Surrogate PMNs and Fig. S1) and are a useful surrogate
model, the biological features of cell lines are often substan-
tially different when compared with those observed in the
corresponding primary human cell. Therefore, we charac-
terized RAR-  mRNA and protein expression in freshly
isolated human PMNs and in PMNs activated with PAF.
Like HL-60 surrogate PMNs, quiescent primary PMNs ex-
press mRNA for RAR-  at baseline (Fig. 2 A). Levels of
the RAR-  transcript did not increase and, in fact, de-
creased after stimulation with PAF (Fig. 2 A). Little or no
RAR-  protein was present in resting PMNs, but in con-
trast it was dramatically induced after cellular activation
with PAF (Fig. 2 A, bottom and not depicted). Recombi-
nant PAF acetylhydrolase, an enzyme that selectively de-
grades PAF (30), blocked expression of RAR-  protein
under these conditions indicating specificity of the agonist
effect (not depicted). This same pattern of RAR-  expres-
sion was seen in an experiment using neonatal PMNs iso-
lated from umbilical cord blood at the time of term deliv-
ery and stimulated with PAF under conditions similar to
those used for PMNs from adult donors (not depicted). In
addition to PAF, TNF , lipopolysaccharide, and n-formyl-
methionyl-leucyl-phenylalanine also triggered rapid syn-
thesis of RAR-  (not depicted). Thus, outside-in signals
delivered by other classes of receptors also induce this re-
sponse, in addition to the PAF signaling pathway.
Rapid de novo expression of RAR-  protein by acti-
vated PMNs suggests an alternate mode of transcriptional
control that contrasts with NF- B, which translocates to the
nucleus and regulates transcription in response to cellular
activation (2, 7). The experiments in Fig. 2 indicate that
RAR-  is also controlled in a signal-dependent fashion, but
its activity requires new synthesis rather than intracellular
translocation of preformed protein from cytoplasmic to nu-
clear compartments as with NF- B. Therefore, we further
characterized features of this event in stimulated PMNs.
Synthesis of RAR-  Protein is Regulated at Translational
Checkpoints in Activated PMNs. Although there is differ-
ential expression of RARs in a variety of cells, most studies
have focused on mechanisms by which RAR-  regulates
the activity of target promoters (12, 31), and pathways that
control synthesis of the protein are not well understood.
Experiments in Fig. 2 A indicated that RAR-  protein is
translated from constitutive mRNA in activated neutro-
phils. When we shortened the time course, we found that
RAR-  protein could be expressed within intervals as
short as 5 min in PAF-stimulated PMNs (Fig. 2 B). This,
together with the discrepancy between RAR-  mRNA
and protein levels in resting PMNs (Fig. 2, A and B), is a
strong indication that RAR-  is under translational control
(10, 13, 22, 23, 28). Actinomycin D, a transcriptional
inhibitor, did not block synthesis of RAR-  protein un-
der these conditions, indicating that its production is con-
trolled post-transcriptionally (Fig. 2 C). In contrast, actino-
mycin D completely inhibited expression of the mRNA
for IL-8 and synthesis of the IL-8 protein (Fig. S2, available
at http://www.jem.org/cgi/content/full/jem.20040224/
DC1), consistent with previous observations that transcrip-
tional regulation is critical in its production by human
PMNs (2). Using similar experimental protocols, actino-
mycin D also selectively inhibited production of other pro-
tein products of stimulated neutrophils (13). Studies with
puromycin and cycloheximide, which are translational in-
hibitors, confirmed that accumulation of RAR-  protein
requires new synthesis in neutrophils activated with PAF
(Fig. 3 A).
Sequence and structure of the 5 -UTR of specific
mRNA transcripts can regulate and suppress their transla-
tion (9–11, 13, 23, 24), although in many cases this has been
examined in model systems and is not well documented in
primary human cells. RAR-  transcripts are differentially
expressed during development as two isoforms,  1 and  2.
The most common isoform, RAR- 1, is found in many
adult tissues (32). Exons 4–10, which cover the majority of
the coding region, are conserved between RAR-  subtypes
(31). However, RAR- 1 and RAR- 2 have different 5 -
UTRs (31) (Fig. 3 B). Therefore, we characterized the 5 -
UTR of the RAR-  mRNA in freshly isolated PMNs us-
ing sequence-specific primers and found that RAR- 1 is
the predominant isoform (Fig. 3 B). In addition, RACE-
PCR, using an internal primer that recognizes a sequence in
the coding region common to both RAR- 1 and RAR-
 2, yielded one dominant band (Fig. 3 B). Cloning and se-
quencing of this product demonstrated that the RAR- 1
isoform is the primary transcript in PMNs.
The 5 -UTR of the RAR- 1 mRNA in PMNs ex-
ceeds 500 nucleotides, is very GC rich, and computer fold-
ing indicates that it contains numerous hairpins and signifi-
cant secondary structure (predicted  G    393.4 kcal/
mol) (Fig. 3 B). Transcripts with 5 -UTR secondary struc-
tures that require energy to unwind exceeding  60 kcal/
mol are often repressed at the translational level (9, 10, 13,
23, 24, 33). Previously, it was noted that sequence features
of the 5 -UTRs of mRNAs coding for RAR isoforms pre-Yost et al. 677
dict translational control (9, 11), but this mode of regulated
expression of their proteins has not been reported in hu-
man leukocytes.
In other cell types, mTOR regulates events that unfold
5 -UTR secondary structure, relieving repression and initi-
ating translation of a subset of key mRNAs that are under
tight synthetic control (13, 23, 24, 33). In parallel studies,
we found that mTOR and its downstream targets (p70S6
kinase and eukaryotic initiation factor-4E binding pro-
tein-1 [4E-BP1]) are present and active in stimulated PMNs
(13), suggesting the possibility that mTOR controls RAR- 
synthesis in response to PAF stimulation. Rapamycin, an
immunosuppressant macrolide, specifically blocks mTOR-
dependent signaling in myeloid leukocytes (13, 23) in
addition to other cell types (33). We found that rapamycin
potently inhibits the synthesis of RAR-  protein in PAF-
stimulated PMNs (Fig. 3 C). In contrast, it had no effect on
the level of actin (Fig. 3 C), a gene product that is indepen-
dent of signal-dependent translational control (23).
Rapamycin is used clinically to prevent rejection after
organ transplantation and to reduce the incidence of vascu-
lar restenosis after interventional procedures in atheroscle-
rotic vascular syndromes (34). It is generally believed that
its therapeutic effects largely involve blocking proliferation
of dividing cells (34, 35). Inhibition of expression of
RAR-  (Fig. 3 C) and a subgroup of other key gene prod-
ucts in PMNs (13), which are terminally differentiated cells
that do not divide, indicates that rapamycin also modulates
other cellular responses and may have previously unrecog-
nized effects on inflammation. Inhibition of RAR-  pro-
tein expression in activated PMNs by rapamycin, which is
a critical molecular probe for the mTOR pathway (33,
36), also provides new insights into the interaction be-
tween specialized translation control pathways and tran-
scriptional regulation (9) in this cell type. Although it has
been observed that homologues of mTOR influence tran-
scriptional activity in response to nutrient stress in yeast
(36) and that mTOR regulates expression of Bcl-3, a
member of the NF- B family of transcriptional regulators,
in other human cells (24, 37) selective translational control
of a transcription factor in activated myeloid leukocytes has
not been reported previously.
RAR-  Regulates the Expression of IL-8 by Activated
PMNs. One mechanism by which RAR-  modulates
transcription is by binding to promoter sequences that con-
Figure 3. Signal-dependent synthesis of RAR-  is regulated at the
translational level by mTOR in human PMNs stimulated by PAF. (A) PMNs
were stimulated with PAF for 30 min in the presence of vehicle alone as a
control (CO); puromycin, or cycloheximide and RAR-  protein levels
were examined by Western analysis. The same samples were simultaneously
probed for  -actin. (Dividing lines indicate elimination of additional con-
centrations of puromycin and cycloheximide from the figure.) These data
are representative of four independent experiments. (B) Stick diagrams illus-
trating the structure of the transcripts for the RAR- 1 and RAR- 2 iso-
forms are shown. A 3 -flanking RACE primer (ccccatagtggtagcctgag) was
directed at exon 4 of RAR-  (see Synthesis of RAR-  Protein is Regu-
lated at Translational Checkpoints in Activated PMNs), which is con-
served in the coding regions of the RAR- 1 and RAR- 2 isoforms. The
5 -UTR of RAR- 1 is derived from exon 1 and a portion of exon 2.
The 5 -UTR of RAR- 2 is derived from a portion of exon 3 and is
shorter than that of RAR- 1. See Zelent et al. (31) for details. The gels
immediately below the stick figures illustrate results of experiments iden-
tifying the RAR-  isoform expressed by human PMNs. The left panel
demonstrates the dominant 5 -UTR RACE product, which is RAR- 1
(see Results and Discussion for details). The right panel illustrates results
of semiquantitative PCR analysis of RAR- 1 and RAR- 2 using prim-
ers specific for their respective 5 -UTRs (as described in Materials and
Methods). These results are representative of two independent experi-
ments. The bottom panel of B illustrates the predicted secondary structure
of the 5 -UTR of RAR- 1 mRNA expressed in human PMNs. (C) PMNs
were pretreated with rapamycin in increasing concentrations and then acti-
vated with PAF, followed by Western blot analysis for RAR-  protein.
Expression of  -actin protein was determined in the same samples. This
result is representative of three independent experiments.Translation of the Retinoic Acid Receptor-  by PMNs 678
tain retinoic acid response elements (RAREs) (12). RAR- 
binds consensus elements more efficiently in the presence
of a second group of retinoic acid receptors, the retinoid
X receptors (RXRs) (12). We found that RXR-  protein
is constitutively present in resting PMNs (Fig. 4 A), indi-
cating that it is available to form RXR-RAR heterodimers
and that RXR  and RAR- 1 are differentially expressed
in this cell type. IL-8 is one of a relatively small number of
RAR-responsive products known to by synthesized by ac-
tivated PMNs among the large group of genes whose ex-
pression is regulated by retinoic acid (12). We found that
mRNA for IL-8 increased after stimulation of PMNs with
PAF (Fig. S2 and Fig. 4 B), consistent with induced syn-
thesis of this chemokine in response to stimulation (2). We
then examined the effect of AM-580, a synthetic retinoid
agonist with specificity for RAR-  (38), under conditions
in which expression of RAR-  and IL-8 is induced. AM-
580 significantly attenuated IL-8 transcript accumulation
after 60 min of stimulation with PAF, whereas treatment of
unactivated PMNs with AM-580 had no effect (Fig. 4 B).
In parallel, we found that PAF-stimulated PMNs synthe-
size significant amounts of IL-8 protein. Treatment with
AM-580 markedly attenuated PAF-induced IL-8 accumu-
lation as measured by ELISA (Fig. 4 C). A similar effect on
PAF-induced IL-8 protein synthesis was noted with all-
trans retinoic acid treatment (not depicted). AM-580 (Fig.
4 C) or all-trans retinoic acid (not depicted) alone did not
significantly alter IL-8 synthesis. We then pretreated
PMNs with rapamycin before stimulation with PAF (Fig. 4
D) to inhibit the induction of RAR-  protein (Fig. 3 C).
AM-580 failed to attenuate synthesis of IL-8 under these
conditions (Fig. 4 D). Together these results indicate that
engagement of newly expressed RAR- 1 by ligands can
alter IL-8 transcription and synthesis of IL-8 protein in
stimulated human PMNs and that mTOR regulates this se-
quence of events by controlling RAR-  translation. Fur-
thermore, they indicate that RAR-  has activities beyond
granulopoiesis (39) in this cell lineage. It is also possible
that unliganded RAR- 1 regulates expression of IL-8 in
PMNs activated with PAF (40). The PAF and retinoid
systems have previously been reported to synergistically
alter expression of cyclooxygenase 2 in neural cells and fi-
broblasts (41), but convergence of these signaling and reg-
ulatory mechanisms has not been observed in myeloid
leukocytes.
Like many retinoid responsive genes the IL-8 promoter
does not contain a classic RARE sequence, indicating that
it may be modulated by RAR-  in an indirect fashion
(12). Genes that contain consensus RAREs are less com-
mon and none of them have been identified in PMNs to
date. Indirect regulation usually occurs via an intermediate
transcription factor that is controlled by RAR-  or a non-
classical association of the receptor with another modula-
tory protein or transcription factor (12). These interactions
can lead to protein sequestration and prevention of critical
transactivating protein–protein interactions (12) with im-
paired synthesis of the corresponding protein product.
These features remain to be explored in activated PMNs.
Figure 4. Retinoic acid re-
ceptor pathways regulate signal-
dependent synthesis of IL-8 in
human PMNs. (A) RXR-  and
 -actin protein expression was
determined by Western analysis
in control PMNs and PMNs
stimulated with PAF. (B) The
relative mRNA copy number for
IL-8, normalized to GAPDH, was
analyzed by quantitative real-time
PCR in PMNs treated for 60
min with PAF (10 nM), PAF to-
gether with AM-580, or AM-580
only. The bars represent fold
changes compared with baseline
(left bar), which was arbitrarily
set to 1. The asterisk indicates
statistical significance (P   0.05)
compared with control and the
double asterisk significance (P  
0.05) comparing PAF and PAF/
AM-580 treated PMNs. The data
in this panel indicate the mean  
SEM of four separate experi-
ments. (C) PMNs were activated
with PAF or PAF in the presence
of AM-580 or were treated with
AM-580 alone. The bars indicate
the mean   SEM of five separate experiments. The asterisk identifies statistical significance (P   0.05) between groups treated with PAF or PAF together
with AM-580. (D) PMNs were pretreated with buffer or with rapamycin (10 nM) and then stimulated with PAF (10 nM) in buffer alone or together
with AM-580 for 240 min. The bars indicate the mean   SEM of three separate experiments. The asterisk identifies statistical significance (P   0.05)
between groups treated with PAF and AM-580 or PAF/AM-580 together with rapamycin.Yost et al. 679
Discussion
Synthesis of RAR-  under signal-dependent transla-
tional control is a new feature of gene expression in acti-
vated PMNs that may herald unrecognized regulatory
mechanisms in acute inflammation. Using cDNA array
analysis, we have found that PMNs also express multiple
additional constitutive transcripts in the resting state and
that in response to PAF and other agonists a subset of these
messages is translated in an mTOR-dependent fashion.
One protein product controlled in this manner is the IL-6
receptor  , a soluble factor that mediates signaling of endo-
thelial cells and transition to the mononuclear phase of in-
flammation (13). Regulation of expression of the IL-6 re-
ceptor   protein by signal-dependent translation is consistent
with the general prediction that specialized translational
mechanisms frequently control synthesis of potent biologi-
cally active proteins (9). Rapid translation-dependent syn-
thesis of a transcription factor that can then modulate ex-
pression of a critical chemokine, IL-8, and potentially other
inflammatory factors—as we show here for RAR- —is
also consistent with this analysis and identifies a novel
mechanism of regulatory interplay between transcriptional
and translational systems in activated human PMNs. Such
interplay between transcriptional and post-transcriptional
mechanisms provides the potential for exquisite precision
in timing and magnitude of expression of potent factors
with key biologic activities (9–11) and may be particularly
important in cells with critical and highly regulated func-
tions such as those subserved by PMNs in inflammation.
mTOR is one checkpoint at which specialized translational
control can influence expression and activity of transcrip-
tion factors and other regulatory proteins in response to
outside-in signaling of PMNs. Additional evidence for dif-
ferential expression of mRNAs and their corresponding
proteins in lipopolysaccharide-stimulated PMNs indicates
that regulated translational events occur under these condi-
tions as well (27). Thus, signaling to posttranscriptional check-
points and to translational control mechanisms appears to
be an important determinant of the proteome of activated
neutrophils. As in other specialized cell types, diverse post-
transcriptional mechanisms are likely to operate (11, 22) in
concert with transcriptional regulation to yield specific
protein patterns and PMN phenotypes in the complex set-
ting of the inflammatory milieu.
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